Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2592-2599

  Denning, David W ^a,b   Warn, Peter ^a  

^a HOPE HOSPITAL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; NYSTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; MALE; MOUSE; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0032729623     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2592     Document Type: Article

References (26)

1. Bowden, R., P. Chandrasekar, M. White, J. A. van Burik, J. Wingard, et al. 1998. A double-blind randomised controlled trial of Amphocil (ABCD) versus amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients, abstr. 091, In Abstracts of the International Immunocompromised Host Society Meeting.
2. Bowden, R. A., M. Cays, T. Gooley, R. D. Mamelok, and J.-A. van Burik. 1996. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. 173: 1208-1215.
3. Broughton, M. C., M. Bard, and N. D. Lees. 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34:75-83.
4. Burch, P. A., J. E. Karp, W. G. Merz, J. E. Kuhlman, and E. K. Fishman. 1987. Favourable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5:1985-1993.
5. Caillot, D., O. Casasnovas, A. Bernard, J. F. Couailler, D. Durand, B. Cuisenier, E. Solary, F. Piard, T. Petrella, A. Bonnin, G. Couillault, M. Dumas, and H. Guy. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15:139-147.
6. Chen, W. C., D.-L. Chou, and D. S. Feingold. 1978. Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob. Agents Chemother. 13:914-917.
7. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev. Infect. Dis. 12:1147-1201.
8. Denning, D. W., L. Hall, M. Jackson, and S. Hollis. 1995. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob. Agents Chemother. 39:1809-1814.
9. Denning, D. W. 1996. Therapeutic outcome of invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
10. Denning, D. W., S. A. Radford, K. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome for Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
11. Ellis, M., D. Spence, B. de Pauw, F. Meunier, A. Marinas, L. Colette, R. Sylvester, J. Meis, M. Boogaerts, D. Selleslag, V. Kremery, and W. vonSinner. 1998. An EORTC International multicenter randomised trial (EORTC Number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27:1406-1412.
12. Graybill, J. R., and S. R. Kaster. 1984. Experimental murine aspergillosis: comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am. Rev. Respir. Dis. 129:292-295.
13. Groll, A. H., C. E. Gonzalez, N. Giri, K. Kligys, W. Love, J. Peter, E. Feuerstein, J. Bacher, S. P. Piscitelli, and T. J. Walsh. 1999. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 43:95-103.
14. Hammond, S. M. 1977. Biological activity of polyene antibiotics. W Prog. Med. Chem. 14:106-179.
15. Hebeka, E., and M. Solotorovsky. 1965. Development of resistance to polyene antibiotics in Candida albicans. J. Bacteriol. 89:1533-1539.
16. Heinemann, V., D. Bosse, U. Jehn, B. Kahny, K. Wachhol, A. Debus, P. Scholz, H. J. Kolb, and W. Wilmanns. 1997. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. J. Antimicrob. Chemother. 41:1275-1280.
17. Johnson, E., K. L. Oakley, S. Radford, C. B. Moore, P. Warn, D. W. Warnock, and D. W. Denning. Lack of correlation of in vitro susceptibility testing methods with in vivo outcome for Aspergillus fumigatus for amphotericin B. J. Antimicrob. Chemother.
18. Lass-Flori, C., G. Kofler, G. Kropshofer, J. Hermans, A. Kreczy, M. P. Dierich, and D. Niederwieser. 1998. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42:497-502.
19. Manavathu, E. K., G. J. Alangaden, and P. H. Chandrasekar. 1998. In vitro isolation and antifungal susceptibility of amphotericin B-resistant isolates of Aspergillus fumigatus. J. Antimicrob. Chemother. 41:615-619.
20. Oakley, K. L., C. B. Moore, and D. W. Denning. 1999. Comparison of in vitro activity of liposomal nystatin against Aspergillus species, with those of nystatin; amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob. Agents Chemother. 5:1264-1266.
21. Prentice, H. G., I. M. Hann, R. Herbrecht, M. Aoun, S. Kvaloy, D. Catovsky, C. R. Pinkerton, S. A. Schey, F. Jacobs, A. Oakhill, R. F. Stevens, P. J. Darbyshire, and B. E. Givson. 1997. A randomized comparison of liposomal versus conventional amphotericin B for treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98:711-718.
22. Sandhu, D. K. 1979. Effect of amphotericin B on the metabolism of Aspergillus fumigatus. Mycopathlogia 1:23-29.
23. Thomas, A. H. 1986. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J. Antimicrob. Chemother. 17:269-279.
24. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B "susceptible" and "resistant" A. fumigatus infection in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
25. Walsh, T. J., J. W. Hiemenz, N. L. Seibel, J. R. Perfect, G. Horwith, L. Lee, J. L. Silber, M. J. DiNubile, A. Reboli, E. Bow, J. Lister, and E. J. Anaissie. 1998. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 24:1383-1396.
26. White, M. H., E. J. Anaissie, S. Kusne, J. R. Wingard, J. W. Helmenz, A. Cantor, M. Gurwith, C. Du-Mond, R. D. Mamelok, and R. A. Bowden. 1997. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. 24:635-642.